BP
ANGO icon

Ballentine Partners’s AngioDynamics ANGO Stock Holding History

Ballentine Partners’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,132
Closed -$141K – 894
2024
Q3 		$141K Buy
+18,132
New +$131K ﹤0.01% 778

Other funds holding ANGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ballentine Partners's ANGO Position: Q4 2024 in Review

Ballentine Partners sold out of AngioDynamics (ANGO) in Q4 2024, closing a stake of 18,132 shares — an estimated $141K sold.

Ballentine Partners first reported a position in ANGO in Q3 2024 and held it in 1 quarter. The position peaked at $141K in Q3 2024. 135 funds tracked by Wall St. Rank hold ANGO as of Q4 2024.

  • Ballentine Partners reported no remaining AngioDynamics position as of Q4 2024 after selling out during the quarter.
  • Ballentine Partners sold 18,132 AngioDynamics shares in Q4 2024, an estimated $141K.
  • Ballentine Partners first reported a position in AngioDynamics in Q3 2024 and held it in 1 quarter.
  • Ballentine Partners's AngioDynamics position peaked at $141K in Q3 2024.
  • 135 funds tracked by Wall St. Rank held AngioDynamics as of Q4 2024.

Based on Ballentine Partners's 13F filing for Q4 2024, filed 16 Jan 2025.